In a recent study it has been found that cell therapies is one of the first steps in developing personalised treatments for cancer in people.The study was discussed in the meeting the American Association of Cancer Research (AACR).In the study, the researchers were able to characterise and identify the neoantigens driving the antitumor responses in a patient treated with an anti-PD-1 blockade and isolate the T cell receptors responsible for such effect.Using immune checkpoint inhibitors to treat people with metastatic melanoma has helped transform the way people with the most deadly skin cancer are treated. Despite its success, there are still many people who do not benefit from the treatment.Up until now, adoptive cell therapy, which involves extracting and harvesting T cells from a patient and engineering them in the laboratory, have targeted shared antigens. That restricts many of the people that can potentially be treated with the therapy because not every cancer has the same ...
